Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized trial of sirolimus-based versus standard GVHD prophylaxis after unrelated donor nonmyeloablative HCT
2011-000088-28Phase 3Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Apr 2011
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sirolimus, mycophenolate mofetil and cyclosporine in graft-versus-host disease (GVHD) (2 arms), sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Incidence of acute grade II-IV graft-versus-host disease. Started Apr 2011; status: completed.
02
Drugs
sirolimusmycophenolate mofetilcyclosporine
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on 2011-000088-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000088-28.